- Home
- CADL vs MITT Comparison
CADL vs MITT Comparison
Compare CADL & MITT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CADL | MITT |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | 287.6M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CADL | MITT |
|---|---|---|
| Price | $5.89 | $8.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $19.43 | $9.04 |
| AVG Volume (30 Days) | ★ 743.5K | 180.6K |
| Earning Date | 03-12-2026 | 03-02-2026 |
| Dividend Yield | N/A | ★ 10.44% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.94 |
| Revenue | N/A | ★ $87,678,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $16.68 |
| P/E Ratio | ★ N/A | $9.39 |
| Revenue Growth | N/A | ★ 8.59 |
| 52 Week Low | $4.25 | $5.63 |
| 52 Week High | $13.68 | $9.27 |
Technical Indicators
Market Signals| Indicator | CADL | MITT |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 55.94 |
| Support Level | $5.91 | $8.67 |
| Resistance Level | $6.62 | $8.99 |
| Average True Range (ATR) | 0.38 | 0.22 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 32.57 | 45.24 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About MITT AG Mortgage Investment Trust Inc.
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation.